Effect of LY293111 in combination with gemcitabine in colonic cancer

Rene Hennig, Xian Zhong Ding, Wei Gang Tong, Richard C. Witt, Borko D. Jovanovic, Thomas E. Adrian*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalCancer Letters
Volume210
Issue number1
DOIs
StatePublished - Jul 8 2004

Keywords

  • Colon cancer
  • Gemcitabine
  • Heterotopic xenografts
  • LY293111

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effect of LY293111 in combination with gemcitabine in colonic cancer'. Together they form a unique fingerprint.

Cite this